

Jennifer Molloy
506 W. Howe St., Tempe, AZ 85281
(503) 830-1543

EDUCATION

CCL, Biotechnology, May 2019

Mesa Community College

GPA: 3.75

B.S., Biological Sciences, May 2016

Arizona State University

GPA: 3.24

RESEARCH EXPERIENCE

Virginia D. Piper Center for Personalized Diagnostics at ASU BioDesign Institute, April 2024 - present

Research Specialist

- Perform HD NAPPA assays to screen human samples for potential biomarkers for different cancers
- Analyze and compile data from NAPPA arrays that can be used for statistical analysis

PI: Dr. Ji Qiu, Research Professor

Ivy Brain Tumor Center at the Barrow Neurological Institute, May 2020 – April 2024

Research Technician II, General Supervisor of ANP of CAP/CLIA Lab

- In a CAP/CLIA certified clinical lab, screen brain tumor tissues from >200 patients via next-generation sequencing and immunohistochemistry for personalized recommendation across 8 clinical trials
- Perform analysis of biomarkers in archival and post-treatment operative tissue to assess pharmacodynamic response
- Perform histological embedding and sectioning of clinical and non-clinical tissue samples
- Perform immunohistochemistry assays on 6 pre-clinical research projects pertaining to drug response and effects on mechanisms of disease

PI: Dr. An-Chi Tien, Research Assistant Professor of Pharmacodynamics

University of Arizona College of Medicine-Phoenix, February 2019 – May 2019

Research Intern

- Contributed to research on the role of nuclear pore proteins Nup98, Nup62 and Nup153 in transcriptional memory and the antiviral response to poliovirus in HeLa cells, resulting in the identification of a novel intermediate cleavage product
- Learned and performed western blot and viral plaque assays
- Presented a poster and rapid-fire talk at the 2019 Arizona Symposium of Virology, Immunology, Microbiomes, and Infectious Disease

PI: Dr. Kurt Gustin, Associate Professor, Basic Medical Sciences

RESEARCH INTERESTS

Neuro-oncology, mechanisms of disease resistance, tumor biology and microenvironment, epigenetics, biomarkers, and cell biology.

POSTERS & PRESENTATIONS

Mehta, S., Tien, A.-C., Patel, S., Margaryan T., **Molloy, J.**, Knight, W., Hon, R., Elliott M., Stavnichuk, M., Opachich, Z., Chang, Y.-W., Montgomery, C. Himes, S., Hopkins, B., Tovmasyan, A., Sanai, N. (2022). Tumor Pharmacokinetics, Pharmacodynamics and Radiation Sensitization in Patient-Derived Models of Glioblastoma Treated with the WEE1 inhibitor, Zn-c3. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Sanai, N., Margaryan, T., **Molloy, J.**, Knight, W., Harmon, J., Hong, A., Wanebo, J. Kennedy, B., Garcia, M., Barani, I., Yoo, W., Tien, A.-C., Tovmasyan, A., Mehta, S. (2022). A Phase 0 'Trigger' Trial of Niraparib in Newly-Diagnosed Glioblastoma Patients. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Sanai, N., Chang, Y.-W., Jiang, J., **Molloy, J.**, Pennington-Krygier, C., Harmon, J., Hong, A., Wanebo, J., Kennedy, W., Garcia, M., Barani, I., Yoo, W., Tovmasyan, A., Tien, A.-C., Li, J., Mehta, S. (2022). A Phase 0 'Trigger' Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma Patients. Abstract presented at 2022 Society of Neuro-Oncology Annual Meeting.

Huttenlocher, D., **Molloy, J.**, Patel, S., Stavnichuk, M., Opachich, Z., Elena, L., White, C., Mehta, S., Tien, A.-C. (2022). Temporal characterization of pharmacodynamics changes with combination treatment of valproic acid and irradiation in intracranial glioma patient-derived xenograft mouse models. Summer intern presentation, Department of translational science, Barrow Neurological Institute.

Molloy, J., Le, S., Sullivan, B.E., Gustin, K. E. (2019). Epigenetic transcriptional memory attenuates virus replication. Poster and Presentation at Arizona Symposium on Virology, Immunology, Microbiomes, and Infectious Disease.

PUBLISHED ABSTRACTS

Chang, Y.W., DeSantis, A., Pennington-Krygier, C., **Molloy, J.**, Mehta, S.; Sanai, N., & Tien, A.C. (2021). Feasibility of Single-Pass Stereotactic Needle Biopsy in Recurrent Glioblastoma Patients to Support CLIA-Certified Tumor Pharmacodynamics for a Phase 0/2 Clinical Trial. *Neuro-Oncology*, 23(Issue Supplement_6), vi63. <https://doi.org/10.1093/neuonc/noab196.245>,
Mehta, S., Tovmasyan, A., Tien, A.C., Holter, M., Hopkins, B., Margaryan, T., Chang, Y.W., Himes, S., Elliot, M., Melendez, E.L., Pennington-Krygier, C., White, C., **Molloy, J.**, Liu, M., Knight, W., & Sanai, N. (2021). Tumor Pharmacokinetics, Pharmacodynamics and Radiation Sensitization in Patient-Derived Xenograft Models of Glioblastoma Treated with the Aurora Kinase A Inhibitor LY3295668. *Neuro-Oncology*, 23(Issue Supplement_6), vi165. <https://doi.org/10.1093/neuonc/noab196.648>

Sanai, N., Margaryan, T., **Molloy, J.**, DeSantis, A., Harmon, J., Hong, A., ... Mehta, S. (2023). A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma. *Journal of Clinical Oncology*, 41(Number 16_suppl), 2051–2051. <https://doi.org/10.1200/JCO.2023.41.16suppl.2051>

TECHNICAL SKILLS

Computational: Aperio ImageScope, Microsoft Office suite, Google suite, Smartsheet, redCap

Laboratory: Next-generation sequencing (Qiagen, Illumina), pyrosequencing (Qiagen), immunohistochemistry (Leica), gel electrophoresis, western blot, ELISA assays, cell culture, viral plaque assays, histological sectioning, DNA/RNA extraction

Other: CITI certified, experience working in a CAP/CLIA accredited lab, CAP inspector trained